Epi-Show Epi-Show. Augmented Reality displaying Brain Signal to guide Epilepsy Surgery
- Coordinator
- Universitair Medisch Centrum Utrecht, Netherlands
- Runs
- 1 June 2026 to 30 November 2027
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 4 organisations in 2 countries
- Type
- European Research Council grant
- Grant agreement
- 101292143
What the project is doing
In the project's own words, from its summary on CORDIS.
Epilepsy surgery is the only curative treatment for focal epilepsy, which affects over 40 million people worldwide. Surgical success depends on correct delineation of diseased tissue, e.g., with intraoperative electrocorticography (ioECoG). IoECoG could profit from recent technical advancements: 1) rapid production of soft and flexible high-density instead of handmade low-density electrode grids enabling precise en sensitive recordings; 2) signal analysis, like the discovery of epileptic high frequency oscillations above 80 Hz, advanced baseline signal analysis algorithms and machine learning.
In current clinical practice, the ioECoG signal is interpreted visually and findings are then orally communicated to the neurosurgeon. To employ ioECoG advancements, we need direct visual interoperability between the measurements, the analyses, and the neurosurgeon. Our proposed solution is using augmented reality to streamline the clinical work-flow and communication between neurophysiologists and neurosurgeons, simultaneously providing a flywheel for research and innovation, now stuck in time-consuming backward estimations of ioECoG electrode grid localisations.
We added a company that is valorising augmented reality for neurosurgery (Augmedit) to our existing consortium between our epilepsy surgery referral center, an industrial product design company and ioECoG grid manufacturing company. We will adapt hardware and neurosurgical augmented reality software to directly recognize three types of ioECoG grids and project them into augmented reality space including the MRI cortical rendering.
This enables direct 3D localisation of the ioECoG and its signal. The software will visualize relevant signal analysis results. The product will be integrated within Augmedit software and optimized using phantoms. The end goal is a test session in human during epilepsy surgery. We will explore future valorisation strategies to potentiate optimal transition to broad clinical use.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Coordinator |
| Neurosoft Bioelectronics SA | Pregny-Chambesy | Switzerland | Participant |
| Augmedit BV | Naarden | Netherlands | Participant |
| Souhoka Tessa | Den Haag | Netherlands | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI